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increases serum Ca 2ϩ concentration in vivo, an action counteracted by activation of the Ca 2ϩ -sensing receptor (CaSR), which decreases parathyroid hormone (PTH) secretion and increases renal Ca 2ϩ excretion. Relatively little is known of the role the CaSR plays in this response through its potentially direct actions in kidney, gut, and bone independently of PTH. We report PTH-independent roles of the CaSR in modulating the response to exogenous 1,25(OH)2D3 in mice with targeted disruption of both the CaSR and PTH genes (C Ϫ P Ϫ ) compared with that in mice with disruption of the PTH gene alone (C ϩ P Ϫ ) or wild-type mice (C ϩ P ϩ ). After intraperitoneal injection of 0.5 ng/g body wt 1,25(OH)2D3, peak calcemic responses were observed at 24 h in all three genotypes in association with 1) a greater increase in serum Ca 2ϩ in C Ϫ P Ϫ mice than in the other genotypes on a Ca 2ϩ -replete diet that was attenuated by a Ca 2ϩ -deficient diet and pamidronate, 2) increased urinary Ca 2ϩ -to-creatinine ratios (UCa/Cr) in the C ϩ P Ϫ and C ϩ P ϩ mice but a lowered ratio in the C Ϫ P Ϫ mice on a Ca 2ϩ -replete diet, and 3) no increase in calcitonin (CT) secretion in the C ϩ P ϩ and C ϩ P Ϫ mice and a small increase in the C Ϫ P Ϫ mice. PTH deficiency had the anticipated effects on the expression of key genes involved in Ca 2ϩ transport at baseline in the duodenum and kidney, and injection of 1,25(OH)2D3 increased gene expression 8 h later. However, the changes in the genes evaluated did not fully explain the differences in serum Ca 2ϩ seen among the genotypes. In conclusion, mice lacking the full-length CaSR have increased sensitivity to the calcemic action of 1,25(OH)2D3 in the setting of PTH deficiency. This is principally from enhanced 1,25(OH)2D3-mediated gut Ca 2ϩ absorption and decreased renal Ca 2ϩ excretion, without any differences in bone-related release of Ca 2ϩ or CT secretion among the three genotypes that could explain the differences in their calcemic responses. vitamin D; kidney THE CALCIUM-SENSING RECEPTOR (CaSR) controls the secretion of parathyroid hormone (PTH), which, in turn, via direct and/or indirect actions on kidney, bone, and intestine, maintains normal extracellular ionized calcium (Ca o 2ϩ ) levels (3) . There is limited understanding of direct functions of the CaSR expressed in tissues other than the parathyroid gland that are involved in overall Ca o 2ϩ homeostasis (27) . Several studies have supported a role of the CaSR in regulating the function of calcitonin (CT)-secreting C cells (10) , and the CaSR plays several putative roles in regulating renal function (2, 14) , but the evidence implicating the receptor in regulating the functions of bone (6 -8, 20) and/or the gastrointestinal (GI) tract (4) is limited and/or controversial. Recent studies, however, in mice with conditional knockout of the receptor in chondrocytes or osteoblasts have implicated the CaSR as a key regulator of these two cell types (5 (11) .
In preliminary studies characterizing mice with homozygous knockout of exon 5 of the CaSR and/or the PTH genes, we observed an altered homeostatic response of mice with knockout of both genes to exogenous 1,25(OH) 2 D 3 administration that was related to the absence of the CaSR gene. On the basis of these studies, we sought to investigate in more detail the in vivo functional and molecular aspects of CaSR-mediated, PTH-independent modulation of responses to exogenous 1,25(OH) 2 D 3 . We used three genotypes of mice [(CaSR
] to evaluate responses to 1,25(OH) 2 D 3 in vivo and to measure the expression of key genes expressed in the kidney and duodenum that are involved in Ca 2ϩ transport and 1,25(OH) 2 D 3 catabolism. We compared the C ϩ P Ϫ and C Ϫ P Ϫ mice to assess roles of the CaSR that are independent of the effects of PTH and compared the C ϩ P Ϫ and C ϩ P ϩ mice to determine actions of PTH per se.
MATERIALS AND METHODS
Materials. 1,25(OH)2D3 and primers for genotyping experimental mice were obtained from Sigma-Aldrich (St. Louis, MO). Pamidronate was obtained from Toronto Research Chemicals (Toronto, ON, Canada). Serum calcitonin (CT) levels were determined using an immunoradiometric rat/mouse CT assay (ALPCO Diagnostics, Salem, NH). Commercial kits were used for measuring serum and urine Ca 2ϩ levels (Eagle Diagnostics, De Soto, TX). Urine and serum creatinine levels were measured using the Stanbio creatinine kit (Stanbio Laboratory, Boerne, TX). Serum 1,25(OH)2D3 levels were determined using a competitive enzyme immunoassay (IDS, Fountain Hills, AZ). Total RNA and cDNA were prepared from harvested tissues using kits obtained from Qiagen (Valencia, CA). Proprietary TaqMan exonspanning primers for real-time PCR with a final concentration of 900 nM and a 6-FAM dye-labeled TaqMan MGB probe with a final concentration of 250 nM were obtained from Applied Biosystems (Foster City, CA).
Rationale behind use of the exon 5 CaSR/PTH and PTH knockout mouse models. The neonatal lethality of the homozygous CaSR knockout (KO) mice has limited their utility for detailed studies of the CaSR's physiological roles in vivo. However, several other mouse models are available for such investigations (14, 28) . One such model "rescues" the homozygous CaSR KO mice by crossing heterozygous CaSR KO mice with mice in which the PTH gene has been knocked out, and this model has established that the CaSR contributes importantly to the fine control of the serum Ca 2ϩ concentration (14) . None of these models have evaluated in any detail the role of the CaSR in C-cell, kidney, and other tissues in maintaining Ca o 2ϩ homeostasis in not only the absence but also the presence of PTH (e.g., given via infusion). This rescued mouse model was developed using the original mouse KO model in which exon 5 of the CaSR was disrupted by insertion of the neo gene (14) . It has subsequently become clear, however, that an alternatively spliced CaSR, lacking exon 5, can be generated in some tissues in homozygous KO mice of this genotype (23, 24 ). It has not been possible to express this truncated receptor at high levels on the cell surface in heterologous systems, precluding direct documentation that it actually has activity, but chondrocytes from exon 5 CaSR KO mice still respond to Ca o 2ϩ , indirectly suggesting that the CaSR lacking exon 5 may have biological activity in certain tissues.
Recent investigations have addressed this latter point by utilizing mice with conditional KO of the CaSR in chondrocytes and osteoblasts, which were generated by crossing mice with floxed exon 7 of the CaSR with appropriate Cre-expressing mice (5) . These studies have shown much more severe skeletal phenotypes than the global exon 5 KO mice, suggesting that the global CaSR Ϫ/Ϫ mice lacking exon 5 are hypomorphic with respect to functions of the CaSR in cartilage and bone, i.e., the CaSR lacking exon 5 can partially or fully rescue the function of these two cell types. Curiously, the mice utilized in the studies of Chang et al. (5) appear to have PTHdependent hypercalcemia (ϳ11.5-13 mg/dl), which is of uncertain significance.
Nevertheless, the original "unrescued" exon 5 KO mice clearly have severely deranged Ca o 2ϩ -regulated PTH release and parathyroid cellular proliferation and relative hypocalciuria that leads to death shortly after birth, as is seen in human neonatal severe hyperparathyroidism due to homozygous inactivating mutations of the CaSR. Moreover, the C Ϫ P Ϫ mice show a nearly complete loss of high Ca o 2ϩ -stimulated CT secretion and a near total failure to increase renal Ca 2ϩ excretion during marked hypercalcemia induced by a PTH infusion (13 Genotyping. For the purpose of genotyping during generation of the three genotypes of experimental mice from the double heterozygotes CaSR ϩ/Ϫ PTH ϩ/Ϫ , genomic DNA was isolated using a Qiagen DNeasy kit. To determine the genotype at both the Pth and CaSR loci, we carried out four PCR amplifications for each animal. To document the presence of the wild-type Casr allele, we amplified DNA samples with Casr forward primer (5Ј-TCATTGATGAACAGTCTTTCTC-CCT-3Ј) and Casr reverse primer (5Ј-TCTGTTCTCTTTAGGTCCT-GAAACA-3Ј). To document the presence of the KO CaSR allele, we used Neo forward primer (5Ј-TCTTGATTCCCACTTTGTGGT-TCTA-3Ј) with Casr reverse primer (5Ј-TCATTGATGAACAGTCTT-TCTCCCT-3Ј). The wild-type Pth allele was detected using PTH forward primer (5Ј-GATGTCTGCAAACACCGTGGCTAA-3Ј) and PTH reverse primer (5Ј-TCCAAAGTTTCATTACAGTAGAAG-3Ј). The null Pth allele was documented using a Neo forward primer (5Ј-TCTT-GATTCCCACTTTGTGGTTCTA-3Ј) and PTH reverse primer (5Ј-TC-CAAAGTTTCATTACAGTAGAAG-3Ј). All PCR reactions were performed using ABI GeneAmp PCR System 9700.
In vivo testing. Several sets (n ϭ 8 -12/set) of 3-to 4-mo-old, nonpregnant female mice homozygous for KO of the CaSR and/or PTH genes or neither (group 1, wild type C ϩ P ϩ ; group 2, C ϩ P Ϫ ; and group 3, C Ϫ P Ϫ ) were administered 0.5 ng/g body wt 1,25(OH)2D3 by intraperitoneal (ip) injection. All experiments were started in the early morning, and the calcemic responses over 72 h were analyzed by obtaining serial 5-l serum samples by cheek bleeding. Serum 1,25(OH)2D3 levels were measured at baseline and at 1 and 24 h by obtaining 100-l serum samples on a separate cohort of mice in keeping with good animal experimentation practices. Serum CT levels were analyzed at baseline and at 24 h by obtaining 100-l samples on yet another cohort of mice. Spot UCa/Cr ratios were analyzed at baseline and at 24 h in several cohorts of mice used for experimentation. Ten-to twenty-microliter samples of acidified clean-catch urine at the appropriate time points were obtained during spontaneous voiding or bladder compression by gentle lower abdominal compression. Injections were given to mice with free access to a Ca 2ϩ -replete diet [0.8% Ca 2ϩ (wt/wt) chow and plain water (e.g., without any added Ca 2ϩ )]. This was repeated in separate groups of mice with or without pretreatment with pamidronate (2.5 g/g body wt ip daily for 2 wk) and subsequent conditioning for 48 -72 h on a Ca 2ϩ -deficient diet (0.01% Ca 2ϩ chow and plain water) before 1,25(OH)2D3 administration. This dose was based on earlier studies, which had shown that pamidronate administered at somewhat lower doses than we used significantly inhibited bone resorption in rats and mice (12, 16) .
Real-time PCR. Total RNA was isolated from kidney and duodenum from several sets of animals separate from those used for physiological measurements under conditions of normal chow and plain water as well as 8 h after ip administration of 0.5 ng/g body wt 1,25(OH)2D3 using Qiagen RNAeasy kits according to the manufacturer's protocol and subsequently treated with RNase-free DNase to remove genomic DNA. These time points were chosen on the basis of prior studies, which have shown that renal vitamin D3-24-hydroxylase, a ratelimiting enzyme in the catabolism of vitamin D metabolites, has a peak mRNA expression at 8 h following 1,25(OH) 2D3 ip injection in rats, with return of expression to baseline by 24 h (15, 17) . Similar time courses for maximal expression have been reported in other studies for the transient receptor potential vanilloid (TRPV) channels 5 and 6 in rat intestine (15, 26) . Reverse transcription using 2 g of DNase-treated RNA was performed using Qiagen Omniscript kits on an ABI GeneAmp PCR System 9700.
To determine the relative number of cDNA molecules in the reverse-transcribed samples, we performed quantitative real-time PCR analyses using an ABI 7000 sequence detection system (Applied Biosystems) with 1 l of cDNA, 10 l of ABI TaqMan master mix, 1 l of proprietary TaqMan gene assay, and 8 l of H2O to a final volume of 20 l. Data were normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels as an endogenous control in test samples using a proprietary ABI TaqMan 6-FAM/MGB, non-primer-limited mouse GAPDH endogenous control probe. All amplifications were carried out in duplicate, and the threshold cycle (Ct) scores were averaged for calculations of relative expression values (18) . The C t scores for genes of interest in each sample were normalized against the C t scores for the corresponding GAPDH gene in that sample, and relative expression was determined using the following calculation where the amount of target gene of interest is normalized to GAPDH in control C ϩ P ϩ mice tissue (18): relative expression of target gene in the tissue of interest ϭ 2
Ϫ⌬⌬Ct
, where ⌬⌬Ct ϭ (⌬Ct of experimental group) Ϫ (⌬Ct of C ϩ P ϩ group) and ⌬C t ϭ mean Ct of target gene in the tissue of interest Ϫ mean Ct of GAPDH in the same tissue. Summary information profiles for each proprietary ABI TaqMan gene assay used for real-time PCR are displayed in Table 1 .
Statistics. We evaluated the differences among the three genotypes at baseline and at experimental end points using one-way ANOVA or t-tests as appropriate. All values are means Ϯ SE. Graphical illustrations were generated using Microsoft Excel 2007 software, and statistical analyses were performed using SPSS software (SPSS, Chicago, IL). (Fig. 2) . There was an ϳ7 mg/dl increase in serum Ca 2ϩ in the C Ϫ P Ϫ mice at 24 h. The increase in serum Ca o 2ϩ was much less marked in the C ϩ P Ϫ mice (ϳ3 mg/dl) and even less so in the C ϩ P ϩ mice (ϳ2 mg/dl; see Fig. 2 ) (independent t-test comparison between C Ϫ P Ϫ and C ϩ P Ϫ at 24 h postinjection, P ϭ 0.001). There also was a faster return of serum Ca 2ϩ to preinjection levels in the C Ϫ P Ϫ mice compared with that in wild-type or C ϩ P Ϫ mice. There was no change in the serum creatinine levels of the three genotypes 24 h postinjection, confirming that there were no significant changes in glomerular filtration rate as a result of 1,25(OH) 2 D 3 administration that would explain the subsequent increase in serum Ca 2ϩ (data not shown). D 3 , we determined the dose necessary using an alternate-day dosing schedule to achieve normocalcemia from baseline hypocalcemia in the C ϩ P Ϫ and C Ϫ P Ϫ mice (Fig. 3 ). C Ϫ P Ϫ mice required 0.0625 ng/g body wt 1,25(OH) 2 D 3 to achieve and maintain normocalcemia compared with a dose of 0.4 ng/g body wt 1,25(OH) 2 D 3 in C ϩ P Ϫ mice. Wild-type mice were able to maintain normocalcemia on the same dose used to achieve normocalcemia in the C ϩ P Ϫ mice. The difference in the sensitivity to 1,25(OH) 2 D 3 of the C Ϫ P Ϫ mice relative to the other two genotypes was even more obvious with attempts to induce moderate hypercalcemia (serum Ca 2ϩ concentrations between 12 and 13 mg/dl), where the C Ϫ P Ϫ mice required 0.125 ng/g body wt whereas the C ϩ P ϩ and C ϩ P Ϫ mice required up to 4 ng/g body wt 1,25(OH) 2 (Fig. 4) . On the Ca 2ϩ -deficient diet, the calcemic response at 24 h in the C Ϫ P Ϫ mice was less robust (ϳ5 mg/dl) than on the Ca 2ϩ -replete diet and was similar to the change seen in the C ϩ P Ϫ mice (4.9 mg/dl) but, again, was greater than that in the C ϩ P ϩ mice (ϳ2.5 mg/dl). Therefore, the difference in the responses of the C Ϫ P Ϫ and C (Fig. 5 ). For this, animals were given 2.5 g/g body wt pamidronate daily by ip injection for 2 wk, a dose higher than those previously shown to inhibit bone resorption in rats and mice (12, 16) . During the last 48 -72 h of this 2-wk period, the animals were placed on a Ca 2ϩ -deficient diet before injection of 0.5 ng/g body wt 1,25(OH) 2 D 3 . The mean maximal change in serum Ca 2ϩ response to 1,25(OH) 2 D 3 administration in the C Ϫ P Ϫ mice was 0.5 mg/dl, compared with 1.4 and 0.4 mg/dl, respectively, in the C ϩ P Ϫ and C ϩ P ϩ mice. There was a significant, albeit 3 . Relative sensitivities to repeated ip administration of 1,25(OH)2D3 in wild-type and knockout (KO) mice at doses designed to maintain normocalcemia using an alternate-day dosing schedule. C ϩ P Ϫ mice needed 0.4 ng/g body wt on alternate days to achieve normocalcemia, whereas C Ϫ P Ϫ mice needed only 0.0625 ng/g body wt to achieve normocalcemia. Wild-type mice were able to maintain normocalcemia despite receiving 0.4 ng/g body wt.
RESULTS

Baseline serum
Arrows represent times of administration of 1,25(OH)2D3. Data are means Ϯ SE (n ϭ 6/genotype). (Fig. 6 ). There were no statistically significant changes in CT levels in wild-type and C ϩ P Ϫ mice at 24 h compared with baseline and only a small absolute, although statistically significant, increase in serum CT in the C Ϫ P Ϫ mice, presumably reflecting, at least in part, the known inhibitory effect of 1,25(OH) 2 D 3 on CT gene expression and secretion (22, 25) .
Urinary Ca 2ϩ response after administration of a single dose of 1,25(OH) 2 D 3 on normal chow and plain water.
Because of the critical role of the kidney in Ca 2ϩ homeostasis and to define a PTH-independent role of the CaSR in the kidney in vivo, we evaluated the possible contribution of altered renal Ca 2ϩ handling to the exaggerated calcemic response of the C Ϫ P Ϫ mice after administration of 0.5 ng/g body wt 1,25(OH) 2 D 3 (Fig. 7) . As expected, even in the absence of severe hypercalcemia in the wild-type and C There also were no differences in CYP24A1 expression levels between the genotypes, which rose substantially in all three genotypes after 1,25(OH) 2 D 3 administration.
Changes in duodenal gene expression after administration of a single dose of 1,25(OH) 2 D 3 on normal chow and plain
water. Two key genes involved in the transport of Ca 2ϩ in the duodenum, CalD9k and TRPV6, were evaluated (Fig. 9) . As expected, there were significant increases in TRPV6 mRNA expression in wild-type (2-fold, P ϭ 0.03), C ϩ P Ϫ (8-fold, P ϭ 0.01), and C Ϫ P Ϫ mice (10-fold, P ϭ 0.01). There were similar increases in CalD9k mRNA expression after 1,25(OH) 2 administration across all genotypes but no differences in expression between genotypes.
DISCUSSION
We examined changes in known hormonal feedback loops and the relative roles of various organs participating in the response to exogenous 1,25(OH) 2 D 3 administration in vivo at the functional and molecular levels in mice with or without knockout of the CaSR and/or PTH genes.
We had previously defined the amount of supplemental Ca 2ϩ in the drinking water needed to raise the serum Ca 2ϩ level of the C ϩ P Ϫ and C Ϫ P Ϫ mice to normocalcemic levels [1.5 and 0.75% (wt/vol), respectively] (13). In our preliminary work for this report, however, we noted that the exaggerated response of the C Ϫ P Ϫ mice to ip injection of 1,25(OH) 2 D 3 was readily seen when they were hypocalcemic on normal chow and plain water, which avoided differences in the GI load of Ca 2ϩ to which the various genotypes were exposed. These initial observations prompted evaluation of the relative contributions of the organs and hormonal systems involved in Ca o 2ϩ homeostasis in wild-type and KO animals to the exaggerated hypercalcemic response of the C Ϫ P Ϫ mice to 1,25(OH) 2 D 3 to determine functions of the CaSR independent of CaSR-regulated PTH secretion.
The pharmacokinetic profile observed after administration of a single dose of 1,25(OH) 2 D 3 is consistent with results in other studies (21) , where ip administration of 1,25(OH) 2 D 3 yielded rapid (peak concentration within 1 h) bioavailability of Ͼ90% of the injected dose with no significant differences in plasma clearance. There were no significant differences between baseline and 24-h postinjection 1,25 (OH) 2 D 3 levels for the C ϩ P ϩ and C ϩ P Ϫ mice and a small but significant difference for the C Ϫ P Ϫ mice of uncertain physiological relevance. There were no significant differences across the genotypes in serum 1,25(OH) 2 D 3 levels at 1 or 24 h, suggesting that differences, if any, in clearance of 1,25(OH) 2 D 3 were not critical in defining the differences in calcemic responses seen among the different genotypes. An explanation of the role of the CaSR independent of PTH in dampening the calcemic response to exogenous The mRNA quantified by real-time PCR was calculated as a fold-change ratio relative to the mRNA for GAPDH in wild-type (C ϩ P ϩ ) mice. Data are means Ϯ SE (n ϭ 6 -8/genotype per condition). *P Ͻ 0.05, baseline vs. 8 h within genotypes. Y P Ͻ 0.05, baseline vs.
isons. There were no significant differences for other comparisons for which P values are not given. concentration in the C Ϫ P Ϫ compared with the C ϩ P Ϫ mice also speaks against a reduced rate of clearance of 1,25(OH) 2 D 3 and/or prolongation of its biological actions as factors contributing to the greater calcemic response of the C Ϫ P Ϫ mice. Therefore, it was more likely that variable sensitivities of the genotypes to genomic and/or nongenomic effects of 1,25(OH) 2 D 3 were responsible for the observed differences in calcemic responses.
We then analyzed the calcemic responses to a single ip dose of 1,25(OH) 2 D 3 on a Ca 2ϩ -replete/plain water diet and observed a marked calcemic response in the C Ϫ P Ϫ mice to frankly hypercalcemic levels, in contrast to the responses of the C ϩ P ϩ and the C ϩ P Ϫ mice, which remained within the normocalcemic range. The exaggerated response in C Ϫ P Ϫ mice also persisted after three consecutive doses given 48 h apart as shown in Fig. 3 , supporting our observations of 1) a distinctly different potency of 1,25(OH) 2 D 3 in inducing a calcemic response in the various genotypes, with the C Ϫ P Ϫ mice markedly more sensitive than the other two genotypes and the C ϩ P Ϫ and C ϩ P ϩ mice showing similar sensitivities, and 2) an effective defense against hypercalcemia conferred by the presence of the CaSR in the absence (in the C ϩ P Ϫ mice) or in the presence of PTH (in the C ϩ P ϩ mice) after 1,25(OH) 2 D 3 administration. We also confirmed that an increase in CT was not a major factor in the defense against 1,25(OH) 2 D 3 -induced hypercalcemia in the C ϩ P Ϫ and C ϩ P ϩ mice (see Fig. 6 ), which supports in vitro studies showing that 1,25(OH) 2 D 3 downregulates CT gene expression within hours of its administration (22, 25) . The competing effects of 1,25(OH)2D 3 to decrease CT mRNA expression and of increases in serum Ca 2ϩ to increase CT secretion in vivo likely explain the lack of either a clear rise or fall in CT levels. This is in contrast to our observations of intact and robust increases (Ͼ10-fold) in serum CT in response to an increased dietary Ca 2ϩ load in the drinking water in the C ϩ P ϩ and C ϩ P Ϫ mice and a markedly blunted response in C Ϫ P Ϫ mice (13) . The GI contribution to the observed responses in the C Ϫ P Ϫ mice to 1,25(OH) 2 D 3 administration was significant as revealed by performing the same experiment on a mice fed a markedly Ca 2ϩ -deficient diet, although it is possible that there is some residual Ca 2ϩ absorption of the small amount Ca 2ϩ in the Ca 2ϩ -deficient diet (80-fold lower than Ca 2ϩ -replete diet). Under conditions of a Ca 2ϩ -deplete diet, the exaggerated calcemic response of C Ϫ P Ϫ mice to exogenous 1,25(OH) 2 D 3 was lost compared with C ϩ P ϩ and C ϩ P Ϫ mice, although the two KO genotypes still showed a substantial calcemic response (Fig. 4) . Therefore, by an uncertain mechanism, the CaSR apparently dampens GI Ca 2ϩ absorption in response to 1,25(OH) 2 D 3 administration. Given the known bone-resorptive effect of 1,25(OH) 2 D 3 , the possible contribution of bone to the calcemic responses observed in mice on a Ca 2ϩ -depleted diet was then evaluated by assessing the calcemic response to 1,25(OH) 2 D 3 after inhibition of osteoclastic bone resorption using pamidronate, a nitrogen-containing bisphosphonate, in mice on a Ca 2ϩ -deficient diet (Fig. 5) . Although the quantitative relationship between bone resorption and release of Ca 2ϩ is unknown, the marked reduction in the calcemic response of the C Ϫ P Ϫ and C It is important to note in discussing the gene responses to exogenous 1,25(OH) 2 D 3 administration (on normal chow and plain water) that wild-type mice were normocalcemic at baseline, whereas the C ϩ P Ϫ and C Ϫ P Ϫ mice were hypocalcemic at baseline due to lack of PTH. It is, therefore, possible that the expression of genes such as VDR and CLDN-16 are increased in the C ϩ P Ϫ and C Ϫ P Ϫ mice compared with wild-type mice at baseline in the kidney, presumably in an attempt to correct hypocalcemia. In the case of the VDR, however, the reductions in both serum Ca 2ϩ (and presumably in CaSR activity, at least in the C ϩ P Ϫ mice) and 1,25(OH) 2 D 3 would have been expected to decrease the expression of the VDR (19) . Therefore, the mechanism(s) producing the increased levels of the VDR in the hypocalcemic C ϩ P Ϫ and C Ϫ P Ϫ mice is uncertain. However, for unclear reasons, there were no differences across all genotypes in baseline expression of TRPV5, NCX1, and NKCC genes in the kidney. The differences in baseline serum Ca 2ϩ levels also may explain differences in the duodenum of baseline expression of PTH/vitamin D-inducible genes TRPV6 and CalD9k (Fig. 9 ), which were higher in the wild-type mice compared with the C (9) . There were differences in basal CYP24A1 (24-hydroxylase) expression among the genotypes. The physiological importance of this observation at baseline under hypocalcemic conditions on the subsequent calcemic responses seen after vitamin D administration is unknown, because there were no significant differences across genotypes in the relative levels of gene expression of the CYP24A1 gene 8 h after 1,25(OH) 2 The CaSR lacking exon 5 also may be upregulated by 1,25(OH) 2 D 3 due to the presence of an intact promoter site, and it might be functional in mediating responses to Ca 2ϩ in some or all tissues studied presently. However, if this is true, the CaSR lacking exon 5 in our C Ϫ P Ϫ mice is insufficient to dampen the hypercalcemic effect of 1,25(OH) 2 D 3 , and as such, our results may even underestimate the role of the CaSR in this response. Interestingly, evaluation of the expression of several key genes known to be involved in renal Ca 2ϩ transport before and 8 h after 1,25(OH) 2 D 3 administration showed upregulation of only the NCX1 gene in C Ϫ P Ϫ mice as a possible explanation of the decreased urinary Ca 2ϩ excretion in the C Ϫ P Ϫ mice 24 h after 1,25(OH) 2 D 3 administration. It is possible that variable kinetics of gene turnover for the genes analyzed in this study have made the search for culprit genes difficult to ascertain in our studies. Furthermore, other transporters or channels not evaluated, such as PCMA1b or CLDN-19, may be culprits. Finally, the CaSR may be involved in the regulation of trafficking of key Ca 2ϩ transporters and channels to the cell surface as has been described for aquaporin-2 in vivo and in vitro.
In conclusion, the full-length CaSR, independent of PTH, is required to dampen the calcemic response to exogenous 1,25(OH) 2 
